Denise Hamilton, founder and CEO of WatchHerWork, is publishing a book that helps guide Black Lives Matter allies to make changes that will help them change the world. Photo courtesy of WatchHerWork

If you went to school in America, you might have been taught that George Washington's teeth were made out of wood. While this information might have been effective in promoting oral health as a kid, it's important for you to know that George Washington's dentures were not made of wood. They were made of ivory, metal alloys, and other human teeth — usually pulled from slaves.

History seems to have been rewritten in this case, and it's not the first — nor the last — time that's happened. Denise Hamilton wants individuals to recognize moments, acknowledge them, and move forward toward the truth. That's why she's publishing a thoughtful journal entitled "Do Something: An Ally's Guide to Changing Yourself So You Can Change Your World."

"I feel really strongly that we all have these challenging stories in our minds that we have to identify and release," Hamilton shares on this week's episode of the Houston Innovators Podcast. "I give that example so that we all are clear that we don't have the full story for a lot of these topics. To me, if you allow yourself to be humble and be open to the fact that you really cannot believe everything you think, we can make so much progress in this space."

Hamilton founded her company, WatchHerWork, five years ago to act as a platform for women seeking career advice and mentorship.

"I had been an executive for many years — around 25 years at this point — and I had been the only woman or the only African American in so many situations that people wanted to pick my brain or take me to lunch," she says. "Frankly, there weren't enough hours in the day."

The company evolved to more, and now she's focused on diversity and inclusion consulting and leadership.

In the months following the death of George Floyd, Hamilton has seen companies react in various ways to the resurgence of the Black Lives Matter movement with marketing campaigns and initiatives for improving workplace conditions.

"The biggest challenge is the same thing that's the biggest opportunity," she says. "Every company has the opportunity to reinvent their approach to how they handle systemic racism in their organizations, and they are terrified by it."

As Hamilton has seen first hand, companies are navigating a minefield of how to react. In her consulting with companies, Hamilton has advised business leaders to be transparent and recognize if they haven't been an ally in this space — and to not act like it. Disclose the things that are being improved and amplify the work that's already been done — don't reinvent the wheel, she says.

"And if you turn this moment into a marketing event instead of a true seed change, we can spot that a mile away. Lead with authenticity, be sincere, and be honest," she says.

The other ongoing challenge Hamilton is navigating with her work is the effect COVID-19 has had on women in the workplace. The pandemic has amplified existing gender issues in the workplace and created new challenges as well. In the past, female executives have been able to climb the corporate ladder while hiring services to help on the home front, but COVID-19 pulled the rug out from under these women's feet.

"Women are starting to opt out because they are overwhelmed," Hamilton says, adding that this thought terrifies her. "We shouldn't live in a society that penalizes you for having children — that's just the bottom line."

What employers have to realize — and this is a cornerstone of Hamilton's work — is that inclusion in the workplace isn't treating everyone the same. It's factoring everyone's differences.

"I don't want you to treat me the same. I want you to look at my situation and treat me the way I need to be treated based on my situation," she says. "And that can be difficult to navigate, but that's what we help our clients do."

As challenging both the social unrest and pandemic has been, it's an opportunity to move forward and make a difference.

"It's a bittersweet experience when there's lots of change — there's always a lot of opportunity as well," Hamilton says. "Never waste a good crisis."

On the episode, Hamilton shares more details about her forthcoming book, advice for female founders, and more. Listen to the full interview below — or wherever you get your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.